Inegy

Simvastatin and ezetimibe, the active ingredients in Inegy, are HMG‑CoA reductase inhibitor and cholesterol absorption inhibitor presented as a tablet for oral prescription use. They lower low‑density lipoprotein cholesterol in patients with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia. GNH USA supplies Inegy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Inegy combines a statin and a cholesterol absorption inhibitor to treat disorders of lipid metabolism. - Hypercholesterolemia: reduces elevated LDL‑cholesterol levels. - Heterozygous familial hypercholesterolemia: improves lipid profile in genetically predisposed patients. - Primary hyperlipidemia: assists in achieving target cholesterol concentrations when diet and lifestyle are insufficient.

Inegy may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate pain often occurring early in therapy. - Abdominal pain: discomfort or cramps in the stomach region. - Diarrhoea: loose stools that may be transient. - Muscle aches: mild myalgia without weakness. - Nausea: feeling of sickness, sometimes with loss of appetite.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown that can lead to kidney injury. - Hepatic enzyme elevation: significant increase in ALT or AST indicating liver stress. - Severe allergic reaction: rash, swelling, or anaphylaxis requiring immediate care. - Myopathy with weakness: muscle weakness accompanied by elevated CK levels. - Pancreatitis: inflammation of the pancreas presenting with abdominal pain and vomiting.

Before initiating therapy, several safety considerations should be reviewed. - Liver function monitoring: obtain baseline and periodic liver enzyme tests. - Renal impairment: assess kidney function and adjust if necessary. - Drug interaction review: evaluate concomitant medications for potential interactions. - Pregnancy and lactation: avoid use unless the potential benefit justifies the risk. - Myopathy risk: advise patients to report unexplained muscle pain or weakness promptly. - Store at room temperature: keep in the original packaging, protect from moisture and heat.

Inegy can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): may markedly increase simvastatin concentrations. - Gemfibrozil: combined use raises the risk of myopathy and rhabdomyolysis. - Cyclosporine: can elevate statin levels, increasing toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Niacin: can increase the likelihood of muscle toxicity. - Antacids containing aluminum or magnesium: may reduce ezetimibe absorption, affecting efficacy.